Pfizers Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Nave, High-Risk Non-Muscle Invasive Bladder Cancer
Pivotal Phase 3 CREST trial results show a 32% reduction in the…
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
April 23, 2025 17:23 ET | Source: Mineralys Therapeutics, Inc. – Significant…
Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to Partners Including Fujirebio and University Hospital Heidelberg
TOKYO, April 23, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025
April 17, 2025 16:30 ET | Source: iRhythm SAN FRANCISCO, April 17,…
Endometriosis Awareness Month: Manipal Hospital Old Airport Road Hosts Expert Session on Diagnosis & Treatment
BANGALORE, India, April 14, 2025 /PRNewswire/ -- In India, menstrual pain is often…
Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's…
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
April 10, 2025 16:05 ET | Source: Adaptive Biotechnologies SEATTLE, April 10,…
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”)…
CAS and Cleveland Clinic collaborate to accelerate research through advanced AI and quantum computing
COLUMBUS, Ohio, April 7, 2025 /PRNewswire/ -- CAS, a division of the…
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified…